A counteracting agent from a patient who recuperated from SARS has appeared to square COVID-19 disease in a lab setting, scientists said on Monday in another potential discovery in the quest for coronavirus treatment.

Researchers situated in Switzerland and the United States recently disconnected the antibodies from the patient in 2003, after the SARS flare-up that murdered 774 individuals. They explored different avenues regarding 25 distinct sorts of antibodies - which target explicit protein spikes on infections - to check whether they could forestall cells getting tainted with COVID-19.

Both SARS and the pathogen which causes COVID-19 are coronaviruses, thought to have originated from creatures, thus their structures are comparable.

The scientists recognized eight antibodies that could tie to both COVID-19 and the contaminated cells.

One applicant, known as S309, was appeared to have "especially solid killing action" against COVID-19.

By joining S309 with different less strong antibodies they had the option to target various destinations on the infection's protein spike, hence decreasing its capability to transform.

The COVID-19 pandemic has seen many preliminaries for compelling treatment propelled, including some including the utilization of antibodies from recouped patients.

While there were no analyses on people in the investigation, distributed in the diary Nature, its writers said their discoveries speak to "evidence of-idea" that antibodies from SARS can forestall serious COVID-19 contamination and spread.

"These outcomes make ready for utilizing S309-and S309-containing counteracting agent mixed drinks for prophylaxis in people at high danger of introduction or as a post-presentation treatment to restrict or treat serious malady," they composed.